These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 25319961)

  • 1. Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
    Gabbert TI; Hoffmeister B; Felsenberg D
    J Cancer Res Clin Oncol; 2015 Apr; 141(4):749-58. PubMed ID: 25319961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
    Vahtsevanos K; Kyrgidis A; Verrou E; Katodritou E; Triaridis S; Andreadis CG; Boukovinas I; Koloutsos GE; Teleioudis Z; Kitikidou K; Paraskevopoulos P; Zervas K; Antoniades K
    J Clin Oncol; 2009 Nov; 27(32):5356-62. PubMed ID: 19805682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.
    Boonyapakorn T; Schirmer I; Reichart PA; Sturm I; Massenkeil G
    Oral Oncol; 2008 Sep; 44(9):857-69. PubMed ID: 18282788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
    J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study.
    Wessel JH; Dodson TB; Zavras AI
    J Oral Maxillofac Surg; 2008 Apr; 66(4):625-31. PubMed ID: 18355585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.
    La Verde N; Bareggi C; Garassino M; Borgonovo K; Sburlati P; Pedretti D; Bianchi C; Perrone S; Mihali D; Cobelli S; Mantica C; Rizzo A; Farina G
    Support Care Cancer; 2008 Nov; 16(11):1311-5. PubMed ID: 18663482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
    Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
    Dimopoulos MA; Kastritis E; Anagnostopoulos A; Melakopoulos I; Gika D; Moulopoulos LA; Bamia C; Terpos E; Tsionos K; Bamias A
    Haematologica; 2006 Jul; 91(7):968-71. PubMed ID: 16757414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.
    Walter C; Al-Nawas B; du Bois A; Buch L; Harter P; Grötz KA
    Cancer; 2009 Apr; 115(8):1631-7. PubMed ID: 19156913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
    Wang EP; Kaban LB; Strewler GJ; Raje N; Troulis MJ
    J Oral Maxillofac Surg; 2007 Jul; 65(7):1328-31. PubMed ID: 17577497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates and osteonecrosis of the jaw: a retrospective study.
    Murad OM; Arora S; Farag AF; Guber HA
    Endocr Pract; 2007; 13(3):232-8. PubMed ID: 17599853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis.
    Ortega C; Montemurro F; Faggiuolo R; Vormola R; Nanni D; Goia F; Gilardino MO; Aglietta M
    Acta Oncol; 2007; 46(5):664-8. PubMed ID: 17562443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy.
    Jung TI; Hoffmann F; Glaeske G; Felsenberg D
    J Cancer Res Clin Oncol; 2010 Mar; 136(3):363-70. PubMed ID: 19701651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw.
    Abu-Id MH; Warnke PH; Gottschalk J; Springer I; Wiltfang J; Acil Y; Russo PA; Kreusch T
    J Craniomaxillofac Surg; 2008 Mar; 36(2):95-103. PubMed ID: 18234504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bisphosphonate-associated osteonecrosis of the jaw].
    Abu-Id MH; Açil Y; Gottschalk J; Kreusch T
    Mund Kiefer Gesichtschir; 2006 Mar; 10(2):73-81. PubMed ID: 16456688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
    Ngamphaiboon N; Frustino JL; Kossoff EB; Sullivan MA; O'Connor TL
    Clin Breast Cancer; 2011 Aug; 11(4):252-7. PubMed ID: 21729657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04).
    Rathbone EJ; Brown JE; Marshall HC; Collinson M; Liversedge V; Murden GA; Cameron D; Bell R; Spensley S; Agrawal R; Jyothirmayi R; Chakraborti P; Yuille F; Coleman RE
    J Clin Oncol; 2013 Jul; 31(21):2685-91. PubMed ID: 23796998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates in multiple myeloma: an updated network meta-analysis.
    Mhaskar R; Kumar A; Miladinovic B; Djulbegovic B
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003188. PubMed ID: 29253322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
    García Sáenz JA; López Tarruella S; García Paredes B; Rodríguez Lajusticia L; Villalobos L; Díaz Rubio E
    Med Oral Patol Oral Cir Bucal; 2007 Sep; 12(5):E351-6. PubMed ID: 17767097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.